Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1996-09-06
1998-08-25
Henley, III, Raymond
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514561, 514811, A61K 3144, A61K 31195
Patent
active
057983712
DESCRIPTION:
BRIEF SUMMARY
This application is a 371 of PCT/RU96/00006 filed Jan. 4, 1996.
FIELD OF TECHNOLOGY
The present invention pertains to medicine, more particularly to a new pharmaceutical composition endowed with an antialcoholic and nootropic effect.
THE PRIOR ART
The problem of the search for and development of medicinal preparations for treatment of alcoholism remains pressing despite the active efforts of research workers in many countries of the world.
At the present time, a reduction in the use of alcohol is relatively easily achieved with preparations which to some degree produce an alcohol-like effect (tranquilizers, barbiturates, GOBA, antihistamine drugs with the tranquilizing effect). Such therapy, however, is known to lead to the development of toxicomanias significantly complicating the course of alcoholism, as well as reducing mental capacity. In treatment of alcoholism, the use of different psychotropic drugs and sensitizing drugs does not achieve the desired effect either, and, more than that, forms a markedly negative attitude to therapeutic measures.
In this connection, of special importance is the search for and development of new antialcoholic drugs having none of the above-mentioned shortcomings, reducing the pathological attraction and at the same time endowed with nootropic properties (increasing attention, improving memory, mental activity).
There are known preparations SAAVE.TM. and tropamine.TM. produced by Matrix Technologies, Inc. (J. of Psychoactive Drugs, vol. 20 (3), July-September 1988, p. 333). SAAVE.TM. is a combination of amino acids DL-phenylalanine, L-tryptophan, L-glutamine and purodoxal-5-phosphate and is recommended as a dietary supplement to the therapy for the subjects suffering from alcoholism and drug addiction (heroin, opiates, etc.). As compared with SAAVE, tropamine contains more additional substances and includes such amino acids as DL-phenylalanine, L-tyrosine, L-tryptophan, L-glutamine as well as pyridoxal-5-phosphate. It is also a dietary supplement in therapy for drug addicts.
Thus, both preparations are dietary supplements, that is, are used alongside with other therapeutic means and contain L-tryptophan the use of which in drugs and dietary supplements was forbidden by the FDA in 1989. Besides, these drugs have no nootropic effect.
The amino acid-containing mixtures are used for subjects abusing alcohol and suffering from alcololism or in the form of dietary supplements (international application WO 89/04165) or in the form of compositions (FR application No. 2607391) which comprise a full set of substitutable or unsubstitutable amino acids and additionally an abundance of most variable chemical compounds (sugars, polymeric carbohydrates, organic acids, fatty acids, phenol acids, phenol aldehydes, aspirin). In such mixtures, amino acids manifest no specific antialcoholic activity playing the; role of enteral nutrition, and, in the administration to man, are mainly used as a plastic material or the source of amino groups for the maintenance of nitric tissue balance. Certain attention should be paid to the compositions containing amino acid L-methionine in combination with vitamin B.sub.6 (U.S. Pat. No. 4,528,295) and with L-alanine (international application WO 95/04529) employed, respectively, for decreasing the level of acetaldehyde in the blood and for the treatment of alcohol abstinence syndrome. However, the doses of amino acids and vitamin B.sub.6 used in such mixtures exceed 5 to 10-fold the daily requirements which (as is well known) may entail significant disorders in protein and amino acid metabolism and additional marked changes in the vitamin balance and allergic complications. In some pathological conditions (U.S. Pat. Nos. 4,405,629; 4,397,866: international application WO 80/02372) amino acids may be used as precursors for increasing in the brain and the spinal cord the level of serotonin (L-tryptophan), adrenaline (L-phenylalanine and L-tyrosine) and glycine (L-threonine). But in these cases as well, very large doses thereof are used which may result
REFERENCES:
patent: 4397866 (1983-08-01), Wurtman
patent: 4405629 (1983-09-01), Wurtman
patent: 4528295 (1985-07-01), Tabakoff
patent: 4761429 (1988-08-01), Blum
patent: 5559152 (1996-09-01), Komissarova
The Merck Index (11th Ed.), Budavari et al., Merck & Co., Inc., Rahway, N.J. (1989) pp. 894 and 952.
Dialog File: Derwent WPI, 004613843, WPI Acc. No.: 86-117187/18 (JP 61058560) 1986, Nippon Oils & Fats KK.
Komarek, L.., Ceskoslovenska hygiene, vol. 34, No. 7-8, 1989, pp. 385-396.
Lehninger, A., Biochemistry, Moscow, MIR Publishing House, 1974, pp. 603-604.
Meister, A., Biochemistry of Amino Acids, Foreign Literature Publishing House, Moscow, 1961, pp. 64-65, 119-120.
Mashkovsky, M.D., Medicaments, New Wave Publishers, Moscow, 1996, pp. 12, 15, 52, 108, 121, 166-167.
Burbenskaya Natalya Mikhailovna
Gudkova Julia Vasilievna
Komissarova Irina Alexeevna
Kondrashova Tatyana Tikhonovna
Soldatenkova Tatyana Dmitrievna
Henley III Raymond
Moezie M.
LandOfFree
Pharmaceutical composition endowed with an antialcoholic and noo does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical composition endowed with an antialcoholic and noo, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical composition endowed with an antialcoholic and noo will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-36610